Short answer: “Wolverine” is informal shorthand, usually for a two-peptide blend of BPC-157 and TB-500. It is not a scientific name and there is no formal definition of it. The two peptides have separate preclinical literatures, mostly in rodent injury models. One 2026 rat study has tested them together, and its results did not show a clear advantage of the combination over TB-500 alone. This guide explains where the name comes from, summarises what the evidence says for each component and for the pair, and explains what researchers should check before using either one. It is research information, not use advice, and nothing here recommends use in people.
Where the name comes from
The name is borrowed from the comic-book character known for fast recovery. It entered online discussion as a nickname for a combination of two peptides associated with tissue-repair research, and suppliers adopted it as a product label. That origin is a useful warning in itself: it is a marketing-flavoured name that implies an effect, and it carries no scientific content.
In practice, “Wolverine” most often means BPC-157 plus TB-500, while the three-component blend that adds GHK-Cu is usually called GLOW. Our guides on the “big 3” peptides and on judging a GLOW blend cover that neighbouring name. Some sellers use the label loosely, so a buyer should always read the component list rather than rely on the name.
BPC-157: what the literature contains
BPC-157, or “body protection compound 157”, is a pentadecapeptide, 15 amino acids long, derived from a sequence found in human gastric juice. Its literature is large and unusually concentrated: a majority of the animal studies come from a single research group in Croatia. Representative papers include Staresinic et al. (Journal of Orthopaedic Research, 2003), which reported accelerated healing of transected rat Achilles tendon and, in vitro, stimulated growth of tendon cells (tendocytes), and Staresinic et al. (2006), which examined transected rat quadriceps muscle.
The most useful overview is the systematic review by Vasireddi and colleagues (HSS Journal, 2025). It identified 544 articles from 1993 to 2024, included 36 studies, and found that 35 were preclinical and one was clinical: a retrospective study of intra-articular use for knee pain. The authors reported that no clinical safety data were found. Preclinical safety studies were reported as showing no adverse effects across several organ systems, but those are animal findings, not data on people. Our BPC-157 research hub gathers the research in more detail.
TB-500: the fragment and the parent protein
TB-500 is usually described as a short fragment of thymosin beta-4, a 43-amino-acid actin-binding protein. The mechanistic literature mostly concerns the full-length protein, and Goldstein, Hannappel and Kleinman (Trends in Molecular Medicine, 2005) is a standard review. A 2026 narrative review in the Journal of the American Academy of Orthopaedic Surgeons (PMID 42937313) stresses that TB-500 is frequently conflated with full-length thymosin beta-4 despite the absence of validated biological equivalence. That is directly relevant to the Wolverine question, since the second half of the blend is the less well-characterised half. Our TB-500 research hub sets out what is known.
The one study of the combination
The question that people ask most is whether the two together do more than either alone. Until recently, nobody had tested it in a controlled study. A 2026 paper in the Joint Diseases and Related Surgery journal (PMID 42542926) evaluated BPC-157, TB-500 and their combination on Achilles tendon healing in a rat model. Thirty-two male Sprague-Dawley rats underwent standardised tendon transection and repair and were randomised to four groups of eight: control, BPC-157, TB-500 and combined. The study assessed biomechanical strength, histology and collagen expression after four weeks.
The reported pattern was nuanced. Maximum load to failure was higher in the BPC-157 and TB-500 groups than in controls, but reached statistical significance only in the TB-500 group. Histopathological scores indicating better tendon architecture were significantly better in the TB-500 group (Bonar and Movin scores) and in the combined group (Movin score), whereas the BPC-157 group showed numerical improvement without reaching significance. In short, TB-500 alone performed at least as well as the combination on the measures reported in the abstract, and BPC-157 alone did not reach significance.
That is a single small study in rats, with eight animals per group, in one injury model, and it should be treated as a data point, not a verdict. It does, however, illustrate something important: the assumption that a combination is better than its parts has to be tested, and the first test did not confirm it clearly.
What this does and does not tell you
It is worth separating what the evidence supports from what the marketing implies.
- Supported: each peptide has been studied in rodent tissue-repair models, with positive findings reported in several of them.
- Supported: at least one study has compared the combination with each peptide alone in rats, with mixed results.
- Not established: that the combination outperforms either peptide alone.
- Not established: any outcome in people, because the clinical evidence for BPC-157 amounts to one small retrospective report and the evidence for TB-500 as a fragment is essentially absent.
- Not established: long-term safety for either peptide in any setting a reviewer would call adequate.
Readers also ask whether “taking TB-500 with BPC-157” is sensible. That is a use question and this site does not answer it. What the literature says is that the combination has barely been studied.
Anti-doping and regulatory context
Both peptides are on the World Anti-Doping Agency Prohibited List: BPC-157 under non-approved substances (S0) and TB-500 as a derivative of thymosin-β4 under growth factors (S2). Neither is a licensed medicine in the UK, and laboratories should follow current MHRA guidance and their institutional rules. This is not legal advice.
Practical notes for laboratories
- Decide between a blend and singles. A fixed-ratio blend is convenient but removes the ability to test each peptide alone. If your design needs the controls the rat study used, single-component vials are better.
- Read the component list. Confirm amounts and identity for each peptide on the certificate. The blends we list are BPC-157 and TB-500 5 mg / 5 mg and BPC-157 and TB-500 10 mg / 10 mg, and the single-peptide pages are BPC-157 and TB-500.
- Calculate concentrations on paper. The peptide calculator converts mass to concentration for laboratory dilutions.
- Check the certificate. Batches from Peptides Lab UK are HPLC & COA Verified, which documents identity and purity for the batch. It does not document an effect.
For a wider look at TB-500’s other research areas, including cardiac biology, see does TB-500 affect the heart?, and for the older comparison of the two peptides, BPC-157 versus TB-500.
How to read a rodent tendon study
Papers like the ones above are easy to over-read. A few habits help. Look at the group size: eight animals per group, as in the 2026 study, is typical for a rat model and leaves little room to detect modest effects, so a “non-significant” result is not the same as “no effect”. Check whether allocation was randomised and whether the people scoring histology were blinded to the group, since subjective scoring systems such as the Bonar and Movin scales are vulnerable to expectation. Note which outcomes were prespecified and which are reported selectively. Ask how the dose and route in the animal translate, and remember that they do not translate directly to any other species. Finally, ask whether anyone outside the originating laboratory has reproduced the result. The BPC-157 literature in particular has been criticised for being concentrated in one group, so independent replication carries extra weight.
Frequently asked questions
For the supplier-evidence side of this topic, see our best research peptides UK checklist and our guide to where to buy peptides in the UK.
What is the Wolverine peptide blend?
Wolverine is informal shorthand, most often for a blend of BPC-157 and TB-500. It is not a scientific name. Suppliers sometimes use it loosely, so the component list on the product page and certificate should always be checked.
Is Wolverine the same as GLOW?
Usually not. GLOW normally means a three-component blend of GHK-Cu, BPC-157 and TB-500, while Wolverine usually means the two-component BPC-157 and TB-500 blend.
Has the combination of BPC-157 and TB-500 been studied?
Yes, in at least one 2026 rat Achilles tendon study with four groups of eight animals. TB-500 alone showed significant improvement on several measures; the combination improved a histology score; BPC-157 alone showed numerical but non-significant improvement. It is a small single-model study.
Should I take TB-500 with BPC-157?
That is a use question and this site does not answer it; our products are for laboratory research only. The research literature on the combination is minimal, and the clinical evidence for each peptide is very limited.
Are BPC-157 and TB-500 banned in sport?
Yes. WADA lists BPC-157 under S0 (non-approved substances) and thymosin-β4 and its derivatives, such as TB-500, under S2 (growth factors). Both are prohibited at all times.
Peptides Lab UK products are supplied for laboratory research use only, not for human or veterinary use. This article is educational and is not medical advice.